Target Price | $79.56 |
Price | $52.82 |
Potential |
50.62%
register free of charge
|
Number of Estimates | 27 |
27 Analysts have issued a price target CRISPR Therapeutics AG 2026 .
The average CRISPR Therapeutics AG target price is $79.56.
This is
50.62%
register free of charge
$281.40
432.75%
register free of charge
$32.32
38.81%
register free of charge
|
|
A rating was issued by 35 analysts: 22 Analysts recommend CRISPR Therapeutics AG to buy, 12 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the CRISPR Therapeutics AG stock has an average upside potential 2026 of
50.62%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 37.31 | 47.88 |
89.95% | 28.32% | |
EBITDA Margin | -1,198.90% | -1,031.51% |
2,095.58% | 13.96% | |
Net Margin | -981.64% | -1,020.09% |
2,272.21% | 3.92% |
28 Analysts have issued a sales forecast CRISPR Therapeutics AG 2025 . The average CRISPR Therapeutics AG sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an CRISPR Therapeutics AG EBITDA forecast 2025. The average CRISPR Therapeutics AG EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
31 CRISPR Therapeutics AG Analysts have issued a net profit forecast 2025. The average CRISPR Therapeutics AG net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -4.34 | -5.53 |
123.71% | 27.42% | |
P/E | negative | |
EV/Sales | 64.86 |
31 Analysts have issued a CRISPR Therapeutics AG forecast for earnings per share. The average CRISPR Therapeutics AG EPS is
This results in the following potential growth metrics and future valuations:
CRISPR Therapeutics AG...
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Aug 07 2025 |
Barclays |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
Chardan Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
RBC Capital |
Locked
➜
Locked
|
Locked | Aug 05 2025 |
B of A Securities |
Locked
➜
Locked
|
Locked | Jul 22 2025 |
Needham |
Locked
➜
Locked
|
Locked | Jul 08 2025 |
Clear Street |
Locked
➜
Locked
|
Locked | Jun 27 2025 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Aug 07 2025 |
Locked
Barclays:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
Chardan Capital:
Locked
➜
Locked
|
Aug 05 2025 |
Locked
RBC Capital:
Locked
➜
Locked
|
Aug 05 2025 |
Locked
B of A Securities:
Locked
➜
Locked
|
Jul 22 2025 |
Locked
Needham:
Locked
➜
Locked
|
Jul 08 2025 |
Locked
Clear Street:
Locked
➜
Locked
|
Jun 27 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.